Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest Update

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) saw a large drop in short interest in the month of November. As of November 15th, there was short interest totalling 13,390,000 shares, a drop of 29.5% from the October 31st total of 18,980,000 shares. Based on an average trading volume of 7,230,000 shares, the short-interest ratio is currently 1.9 days.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Barclays lifted their price objective on Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a research report on Thursday, November 14th. StockNews.com upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a research report on Thursday, November 14th.

Institutional Trading of Sangamo Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of SGMO. State Board of Administration of Florida Retirement System grew its stake in shares of Sangamo Therapeutics by 61.1% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 23,650 shares during the period. Meritage Portfolio Management grew its stake in shares of Sangamo Therapeutics by 8.6% during the 3rd quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 6,740 shares during the period. XTX Topco Ltd grew its stake in shares of Sangamo Therapeutics by 167.8% during the 3rd quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock valued at $90,000 after buying an additional 64,981 shares during the period. Wealth Enhancement Advisory Services LLC grew its stake in shares of Sangamo Therapeutics by 55.4% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock valued at $94,000 after buying an additional 38,850 shares during the period. Finally, Virtu Financial LLC purchased a new stake in shares of Sangamo Therapeutics during the 3rd quarter valued at $150,000. 56.93% of the stock is owned by hedge funds and other institutional investors.

Sangamo Therapeutics Price Performance

SGMO stock traded down $0.04 during midday trading on Friday, hitting $2.26. The stock had a trading volume of 3,004,315 shares, compared to its average volume of 6,875,489. The firm has a market cap of $471.55 million, a PE ratio of -3.07 and a beta of 1.10. Sangamo Therapeutics has a 12-month low of $0.30 and a 12-month high of $3.18. The company’s 50-day moving average price is $1.54 and its 200 day moving average price is $0.96.

Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.07. The firm had revenue of $49.41 million during the quarter, compared to analysts’ expectations of $26.55 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. During the same period in the previous year, the company earned ($0.34) EPS. As a group, sell-side analysts anticipate that Sangamo Therapeutics will post -0.52 EPS for the current year.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.